GLP-1 Medication Arrived Warm? What to Do Before Using It

If a compounded injectable GLP-1 arrives warm or inadequately refrigerated, do not use it. FDA specifically advises against using injectable GLP-1 medication that arrives warm or with insufficient refrigeration because storage problems can affect quality. Contact the dispensing pharmacy and prescriber for the next step¹.

If the delivery is a branded product, identify the exact presentation and follow its labeling and the manufacturer's advice. A room-temperature allowance for one pen is not permission to use a different vial after an unknown shipping exposure. This page addresses a delivery problem; our shelf-life guide covers routine storage and after-opening limits.

Start with what you received

Find the medication name, dispensing pharmacy, concentration, prescription label and delivery record. Check whether you received a manufacturer-sealed branded product or a compounded preparation. Product identity comes before interpreting a temperature allowance.

For example, Zepbound labeling distinguishes presentations and gives storage instructions for them. Those instructions should not be applied to a compounded vial simply because both labels say tirzepatide². The same caution applies when comparing one brand's pen with another brand's injection device.

Do not let the seller's product-page title substitute for the prescription label. If the contents, label and order confirmation do not agree, report that discrepancy along with the shipping concern. A temperature question is harder to resolve if nobody has established which preparation was actually dispensed.

Preserve the information the pharmacy needs

As a practical record, photograph the box, insulation, cooling packs, medication packaging and label. Save the carrier's delivery time and note when the package was opened. If there is a temperature indicator, photograph its reading and instructions. Record a measured temperature only if you actually have one; warm to the touch is an observation, not a precise measurement.

Describe the circumstances without filling in missing facts. The pharmacy needs to know whether the package sat outside, whether there was a delay and how it looked when opened. If you cannot know the temperature history, say so. An invented number makes the assessment less reliable.

These documentation steps are a way to make the conversation concrete, not a method of proving potency at home. A photograph of an ice pack cannot establish the medication's complete transit conditions or confirm that the product remains within specification.

Call the dispensing pharmacy, not only customer support

The pharmacy on the prescription label is the key contact for the preparation's storage instructions and product assessment. A telehealth customer-support agent may handle replacement logistics, but ask whether a pharmacist has reviewed the actual medication and exposure.

A useful message is: my medication arrived on this date, it was opened at this time, this is the product and concentration, and this is what I observed. Ask whether the pharmacy recommends using it, replacing it or holding it while more information is gathered. Request that the advice identify the specific preparation rather than just saying all our packages are fine.

If the label does not identify a real dispensing pharmacy or you cannot reach it, that is a separate concern. FDA's BeSafeRx resources explain how to check an online pharmacy and its state licensure. A telehealth brand name is not itself a pharmacy-license verification³.

Cooling it again does not answer the question

Putting a warm package into a refrigerator does not establish what happened during shipping or prove that any quality change has been reversed. Follow the labeled storage instructions while awaiting advice, but do not mistake later refrigeration for a release decision.

Do not freeze medication to cool it faster or run a home experiment to decide whether it is still active. The useful information is the exact product's instructions and the responsible pharmacist's assessment. A comparison with a forum user's box cannot reproduce the same formulation, route, duration or temperature history.

The question to resolve is whether this medication should be used, rather than whether you can make the packaging look cold again. Keep that distinction explicit when discussing a replacement or refund.

Normal appearance is not proof of acceptable shipping

Follow the product's appearance instructions, but do not use a clear-looking solution as a complete quality test. Manufacturer labeling includes particular checks for particles, discoloration or freezing; those are not an at-home assay of potency, sterility or the full exposure history².

Likewise, melted ice packs alone do not provide a precise account of the medication's temperature throughout transit. Report what you observed and ask for the preparation-specific assessment. Avoid the two extremes of declaring every melted pack a proven damaged drug or declaring every clear vial safe.

If packaging is broken, the vial is leaking or the label is unreadable, include those problems in the same report. A single delivery can have more than one issue, and solving the cooling question would not resolve a separate identity or packaging defect.

Ask for a plan for the next scheduled dose

If the shipment cannot be used, contact the prescriber about the possible treatment gap. Tell them when the last dose was taken and when the replacement is expected. This article does not provide instructions to skip, double, stretch or restart doses.

Do not compensate for a suspected loss of potency by taking more medication. The amount of active drug in a vial cannot be inferred from whether appetite suppression feels weaker. Dose uncertainty and shipping uncertainty should be resolved by the treating professionals rather than combined into a self-directed adjustment.

People using medication for diabetes also need to discuss how a supply interruption affects their broader treatment plan. The replacement process and the clinical plan are related, but they are not the same task. Make sure someone is responsible for both.

Replacement, refund and clinical advice are different questions

Ask what the seller and pharmacy will do, how long it should take and whether the replacement will require a new prescription or authorization. Keep the relevant correspondence and order records. A clear answer is more useful than a general promise that the company stands behind its shipping.

A refund policy does not determine whether medication is medically appropriate to use. Equally, a decision not to use a shipment does not automatically establish the financial remedy in every contract. Separate the pharmacist's product assessment from the customer-service discussion so neither is lost.

When comparing future providers, look for published shipping methods, a reachable pharmacy and a clear process for handling temperature concerns. Our provider reviews and price transparency index can help frame those questions, but a past shipping claim is not a guarantee about a future package.

If you already used it

Tell the pharmacist and prescriber what was used, when and what the delivery problem was. If you have symptoms, describe them and seek appropriate medical assessment rather than assuming they prove a heat-related defect. Trouble breathing or another medical emergency requires urgent care.

FDA encourages reporting problems and adverse events involving unapproved GLP-1 drugs. Such reports can help identify concerns, but an adverse-event report does not by itself establish that a particular temperature exposure caused a symptom¹.

Keep the remaining packaging and medication information available while the professionals advise you. Do not share the shipment with someone else or test it by comparing how different people respond. That creates another problem rather than answering the original one.

The decision to get in writing

Before using the shipment, resolve three things: which exact product is involved, what the responsible pharmacy advises about the observed exposure, and how the prescriber wants any missed treatment handled. For compounded injectable GLP-1s, FDA's warm-delivery warning is explicit.

A calm, specific record makes that process easier. It does not require you to diagnose degradation or prove a cold-chain failure yourself. The medication, the shipping observations and the professional advice should all refer to the same actual delivery.